European Medicines Agency (EMEA): Committee for Medicinal Products for Human Use
(I-Newswire) - The Committee for Medicinal Products for Human Use ( CHMP ) gave positive opinions on initial marketing authorisation applications for
* Aptivus ( tipranavir ), from Boehringer Ingelheim International GmbH, for the treatment of Human Immunodeficiency Virus ( HIV-1 ) infection in highly pre-treated adult patients with virus that is resistant to multiple protease inhibitors. EMEA review began on 15 November 2004 with an active review time of 204 days.
* Kepivance ( palifermin ), from Amgen Europe B.V., for the prevention and treatment of oral mucositis in patients with haematological ( blood and blood-forming tissues ) cancers undergoing myoablative therapy, which suppresses bone marrow activity. EMEA review began on 19 July 2004 with an active review time of 217 days.
* Noxafil ( posaconazole ) and Posaconazole SP ( posaconazole ), from SP Europe, for the treatment of certain invasive fungal infections in patients whose disease ( this is labelled in a confusing way ) did not respond to certain commonly used antifungal agents or who were intolerant of these other agents. EMEA review began on 19 July 2004 with an active review time of 219 days.
* Procoralan ( ivabradine ) and Corlentor ( ivabradine ), from Les Laboratoires Servier, for the treatment of chronic stable angina pectoris. EMEA review began on 17 May 2004 with an active review time of 211 days.
* Revatio ( sidenafil citrate ), from Pfizer Limited, for the treatment of pulmonary arterial hypertension. EMEA review began on 20 December 2004 with an active review time of 177 days. Revatio is the twenty-second orphan medicinal product to receive a positive CHMP opinion.
* Xolair ( omalizumab ), from Novartis Europharm Ltd., for the treatment of severe persistent allergic asthma. EMEA review began on 19 July 2004 with an active review time of 214 days.
* Extensions of indications and other recommendations
* The Committee adopted opinions for the extension of indications of products that are already authorised on the European Union.
* Keppra ( levetiracetam ), UCB S.A., to extend the indication of adjunctive therapy in the treatment of partial onset seizures with or without secondary generalisation to children from 4 years of age with epilepsy. Keppra was first authorised in the European Union on 29 September 2000.
* Remicade ( infliximab ), Centocor B.V., to extend its indication to include treatment of moderate to severe plaque psoriasis in adults who failed to respond to, or who have a contraindication to, or are intolerant to other systematic therapy including cyclosporine, methotrexate or PUVA. Remicade was first authorised in the European Union on 13 August 1999.
The Committee recommended a new contraindication for Forsteo ( teriparatide ) to exclude patients with skeletal malignancies or bone metastases from treatment. Summaries of opinion for initial marketing authorisation applications, extensions of indication and other recommendations are available and can be found here <http://www.emea.eu.int/htms/human/opinion/opinion.htm>.
The Committee finalised an arbitration procedure for Coversyl 2 and 4 mg ( perindopril tert-butylamine salt ) and associated trade names from Les Laboratoires Servier, recommending the extension of the indication to include the reduction of risk of cardiac events in patients with stable coronary artery disease with a history of myocardial infarction and/or revascularisation. Coversyl is authorised in a number of EU Member States and is currently indicated for the treatment of hypertension and symptomatic heart failure. The referral was made by the Netherlands under Article 6( 12 ) of Commission Regulation ( EC ) No 1084/2003.
A more detailed CHMP meeting report will be published shortly.
If you have questions regarding information in this press release contact the company listed below. I-Newswire.com is a press release service and not the author of this press release. The information that is on or available through this site is for informational purposes only and speaks only as of the particular date or dates of that information. As some companies / PR Agencies submit their press releases once per week/month or quarter, make sure check the official company website for accurate release dates as our site displays the I-Newswire.com distribution date only. We do not guarantee the accuracy or completeness of information on or available through this site, and we are not responsible for inaccuracies or omissions in that information or for actions taken in reliance on that information.
Immerse yourself in mystery and magic with two exciting new casual games from Focus Multimedia and Big Fish Games Studios, one of the world’s leading casual game developers. Hidden Expedition Titanic and Azada join Focus’ popular Revival range of super-budget price games and are available in a store near you.
Edraw Max enables students, teachers and business professionals to reliably create and publish kinds of diagrams to represent any ideas. With large pre-drawn libraries and more than 4600 vector symbols, drawing couldn't be easier!
New range of cards launched to make you the cover star.Hallmark Cards in partnership with OK Magazine has launched an exclusive and exciting new range of greeting cards that gives people the chance to give family and friends the A-List treatment.
Many people choose not to pursue an accident claim. The reasons range from knowing the insurance company will settle; to they don't want the legal hassles and expense.
Many individuals and businesses have always purchased their personal computers from a well-known provider to pre-conceived specifications. Increasingly...
The effectiveness of SEO and PPC Services are directly related to the quality and quantity of the performance data that they have to work with. If you are seeking assistance in achieving a higher ranking on search engine results, then we suggest you visit RankYourWebsites.com, specialist in this area. If you have found your attempts at optimization to prove fruitless, the representatives at RankYourWebsites.com will have a solution to increase your traffic.
http://www.vineyardsforsalein.com/ - online island vineyard for sale, vineyard for sale paso, texas vineyard for sale, washington vineyard for sale, tuscany vineyard for sale, vineyard for sale santa, vineyard for sale California
Mark Flanagan, Managing Director of Manchester health and safety, food safety and fire safety consultancy, Shieldyourself, discussed the Scores on the Doors scheme when he made a guest appearance on the BBC’s 5 Live Radio Show recently.
